Basilea Pharmaceutica AG
BPMUF
$77.40
$11.9018.17%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 244.78M | 242.53M | 235.10M | 239.34M | 244.71M |
| Total Other Revenue | 63.93M | 55.58M | 46.37M | 37.07M | 27.87M |
| Total Revenue | 308.71M | 298.12M | 281.48M | 276.40M | 272.58M |
| Cost of Revenue | 189.86M | 184.80M | 176.11M | 160.86M | 146.23M |
| Gross Profit | 118.85M | 113.32M | 105.36M | 115.54M | 126.35M |
| SG&A Expenses | 44.16M | 43.65M | 42.16M | 40.07M | 38.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 234.03M | 228.45M | 218.28M | 200.93M | 184.37M |
| Operating Income | 74.69M | 69.67M | 63.20M | 75.47M | 88.22M |
| Income Before Tax | 73.19M | 65.03M | 55.67M | 69.21M | 83.22M |
| Income Tax Expenses | 7.84M | 7.39M | 6.74M | 3.19M | -381.00K |
| Earnings from Continuing Operations | 65.34 | 57.64 | 48.94 | 66.01 | 83.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.34M | 57.64M | 48.94M | 66.01M | 83.61M |
| EBIT | 74.69M | 69.67M | 63.20M | 75.47M | 88.22M |
| EBITDA | 77.24M | 72.69M | 66.64M | 78.78M | 91.41M |
| EPS Basic | 5.31 | 4.69 | 4.00 | 5.42 | 6.89 |
| Normalized Basic EPS | 3.73 | 3.33 | 2.88 | 3.59 | 4.32 |
| EPS Diluted | 5.00 | 4.47 | 3.84 | 5.06 | 6.31 |
| Normalized Diluted EPS | 3.36 | 3.05 | 2.64 | 3.23 | 3.84 |
| Average Basic Shares Outstanding | 49.22M | 49.10M | 48.97M | 48.82M | 48.68M |
| Average Diluted Shares Outstanding | 54.66M | 53.39M | 53.43M | 53.80M | 54.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |